Cargando…

Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy

This retrospective study aimed to explore the relative efficacy and safety of different tacrolimus (TAC) concentrations in the treatment of patients with idiopathic membranous nephropathy (IMN). A total of 260 IMN patients with nephrotic syndrome (NS) were recruited. Among these, 125 patients had TA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qi, Li, Manna, Cheng, Xuexin, Xu, Gaosi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225915/ https://www.ncbi.nlm.nih.gov/pubmed/34168218 http://dx.doi.org/10.1038/s41598-021-92678-y

Ejemplares similares

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy
por: Zou, Honghong, et al.
Publicado: (2019)

Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy
por: Liang, Qian, et al.
Publicado: (2017)

Efficacy and safety of 12 immunosuppressive agents for idiopathic membranous nephropathy in adults: A pairwise and network meta-analysis
por: Liu, Jiarong, et al.
Publicado: (2022)

Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis
por: Lin, Wenshan, et al.
Publicado: (2019)

Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy
por: Cui, W., et al.
Publicado: (2017)

Effect of Nephritis Rehabilitation Tablets combined with tacrolimus in treatment of idiopathic membranous nephropathy
por: Lv, Wei, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide–corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy
por: Zhang, Chengning, et al.
Publicado: (2020)

Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients
por: Qin, Hua-Zhang, et al.
Publicado: (2017)

Treatment of Idiopathic Membranous Nephropathy for Moderate or Severe Proteinuria: A Systematic Review and Network Meta-Analysis
por: Chen, Miaomiao, et al.
Publicado: (2022)

Efficacy and Safety of Different Immunosuppressive Therapies in Patients With Membranous Nephropathy and High PLA2R Antibody Titer
por: Deng, Le, et al.
Publicado: (2022)

Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients
por: Liang, Shuang, et al.
Publicado: (2023)

Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy
por: Shang, Shun-Lai, et al.
Publicado: (2018)

Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy
por: Zhao, Lijuan, et al.
Publicado: (2023)

Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study
por: Liu, Shanshan, et al.
Publicado: (2015)

Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population
por: Lin, Shujun, et al.
Publicado: (2019)

Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: Lu, Huijuan, et al.
Publicado: (2022)

Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
por: Li, Yebei, et al.
Publicado: (2021)

Retracted: Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: and Biomechanics, Applied Bionics
Publicado: (2023)

Electron-Dense Deposition Patterns and the Outcomes of Nephrotic Idiopathic Membranous Nephropathy Treated with Tacrolimus in Chinese Adults
por: Xiang, Xin, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: a meta-analysis
por: Zhang, Yong, et al.
Publicado: (2018)

Management of anticoagulation and antiplatelet therapy in patients with primary membranous nephropathy
por: Zou, Honghong, et al.
Publicado: (2019)

Comparative Efficacy and Safety of Therapies in IgA Nephropathy: A Network Meta-analysis of Randomized Controlled Trials
por: Yang, Pingping, et al.
Publicado: (2018)

METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of α-klotho
por: Li, Manna, et al.
Publicado: (2021)

Correction to: METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of α‑klotho
por: Li, Manna, et al.
Publicado: (2022)

Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study
por: Chen, Shasha, et al.
Publicado: (2020)

Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy
por: Chen, Xinxin, et al.
Publicado: (2017)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials
por: Huang, Haiting, et al.
Publicado: (2021)

Tacrolimus-induced epilepsy with primary membranous nephropathy: A case report
por: Yang, Yan, et al.
Publicado: (2021)

Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial
por: Nikolopoulou, Aikaterini, et al.
Publicado: (2019)

Efficacy and safety of tripterygium wilfordii multiglycosides in idiopathic membranous nephropathy: Protocol for an open-label randomized controlled clinical trial
por: Geng, Chanyu, et al.
Publicado: (2022)

Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study
por: Zhang, Shasha, et al.
Publicado: (2023)

New-Onset and Relapsed Membranous Nephropathy post SARS-CoV-2 and COVID-19 Vaccination
por: Ma, Qiqi, et al.
Publicado: (2022)

Idiopathic Membranous Nephropathy and Treatment Related Complications
por: Uncanin, Snezana, et al.
Publicado: (2020)

Discussion on machine learning technology to predict tacrolimus blood concentration in patients with nephrotic syndrome and membranous nephropathy in real-world settings
por: Yuan, Weijia, et al.
Publicado: (2022)

An Update on Targeted Treatment of IgA Nephropathy: An Autoimmune Perspective
por: Huang, Xin, et al.
Publicado: (2021)

Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis
por: Zhong, Hongzhen, et al.
Publicado: (2020)

Efficacy and safety of Tripterygium wilfordii multiglucoside for idiopathic membranous nephropathy: a systematic review with bayesian meta-analysis
por: Wang, Hongyun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_njlqeqatn29h9vr71lgfnd7aqp